Literature DB >> 34972736

Epipharyngeal Abrasive Therapy Down-regulates the Expression of SARS-CoV-2 Entry Factors ACE2 and TMPRSS2.

Kensuke Nishi1,2, Shohei Yoshimoto3, Soichiro Nishi2, Toshiyuki Tsunoda4, Jun Ohno5, Michinobu Yoshimura6, Kenji Hiromatsu6, Takafumi Yamano7.   

Abstract

BACKGROUND: The epipharynx, with its high expression of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) entry factors angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2), is a primary target for SARS-CoV-2 replication in the early stage of Coronavirus Disease 19 (COVID-19). Epipharyngeal abrasive therapy (EAT) is a treatment for epipharyngitis in Japan which involves applying zinc chloride to the epipharyngeal mucosa. In this study, we evaluated the expression patterns of ACE2 and TMPRSS2 in tissue samples from patients before and after EAT. PATIENTS AND METHODS: The study subjects were seven patients that had not been treated with EAT and 11 patients that had. For immunohistochemical assessment of the epipharyngeal mucosa, the staining intensity of ACE2 and TMPRSS2 was described as an immunohistochemical score (IHC score).
RESULTS: The IHC scores for ACE2 and TEMPRSS2 in the EAT-treated group were 3.40-fold and 1.81-fold lower, respectively, than those in the non-treated group (p=0.0208 and p=0.0244, respectively).
CONCLUSION: EAT down-regulates the expression of SARS-CoV-2 entry factors ACE2 and TMPRSS2. Thus, EAT has potential as a novel COVID-19 preventative method.
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  ACE2; EAT; Epipharyngeal abrasive therapy; SARS-CoV-2; TMPRSS2

Mesh:

Substances:

Year:  2022        PMID: 34972736      PMCID: PMC8765169          DOI: 10.21873/invivo.12712

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  11 in total

1.  Outcome of an outpatient specialty clinic for chronic epipharyngitis.

Authors:  Manabu Mogitate; Yuko Sasaki; Ayako Komiyama
Journal:  Auris Nasus Larynx       Date:  2020-10-13       Impact factor: 1.863

2.  A Kidney Transplant Recipient with Recurrent Henoch-Schönlein Purpura Nephritis Successfully Treated with Steroid Pulse Therapy and Epipharyngeal Abrasive Therapy.

Authors:  Mika Fujimoto; Kan Katayama; Kouhei Nishikawa; Shoko Mizoguchi; Keiko Oda; Yosuke Hirabayashi; Yasuo Suzuki; Ayumi Haruki; Takayasu Ito; Tomohiro Murata; Eiji Ishikawa; Yoshiki Sugimura; Masaaki Ito
Journal:  Nephron       Date:  2020-11-20       Impact factor: 2.847

3.  Nasal ACE2 Levels and COVID-19 in Children.

Authors:  Ankit B Patel; Ashish Verma
Journal:  JAMA       Date:  2020-06-16       Impact factor: 56.272

4.  IgA nephropathy and psoriatic arthritis that improved with steroid pulse therapy and mizoribine in combination with treatment for chronic tonsillitis and epipharyngitis.

Authors:  Tomohiro Kaneko; Akiko Mii; Megumi Fukui; Kiyotaka Nagahama; Akira Shimizu; Shuichi Tsuruoka
Journal:  Intern Med       Date:  2015-05-01       Impact factor: 1.271

5.  Involvement of chronic epipharyngitis in autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA).

Authors:  Osamu Hotta; Ayaki Tanaka; Akira Torigoe; Kazuaki Imai; Norio Ieiri
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

6.  Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2.

Authors:  Ching-Yuan Wu; Yu-Shih Lin; Yao-Hsu Yang; Li-Hsin Shu; Yu-Ching Cheng; Hung Te Liu
Journal:  Front Pharmacol       Date:  2020-12-17       Impact factor: 5.810

7.  Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.

Authors:  Jesper D Gunst; Nina B Staerke; Marie H Pahus; Lena H Kristensen; Jacob Bodilsen; Nicolai Lohse; Lars S Dalgaard; Dorthe Brønnum; Ole Fröbert; Bo Hønge; Isik S Johansen; Ida Monrad; Christian Erikstrup; Regitze Rosendal; Emil Vilstrup; Theis Mariager; Dorthe G Bove; Rasmus Offersen; Shakil Shakar; Sara Cajander; Nis P Jørgensen; Sajitha S Sritharan; Peter Breining; Søren Jespersen; Klaus L Mortensen; Mads L Jensen; Lilian Kolte; Giacomo S Frattari; Carsten S Larsen; Merete Storgaard; Lars P Nielsen; Martin Tolstrup; Eva A Sædder; Lars J Østergaard; Hien T T Ngo; Morten H Jensen; Jesper F Højen; Mads Kjolby; Ole S Søgaard
Journal:  EClinicalMedicine       Date:  2021-04-22

8.  Nasopharyngeal Expression of Angiotensin-Converting Enzyme 2 and Transmembrane Serine Protease 2 in Children within SARS-CoV-2-Infected Family Clusters.

Authors:  Mohammad Rubayet Hasan; Muneera Naseer Ahmad; Soha Roger Dargham; Hatem Zayed; Alaa Al Hashemi; Nonhlanhla Ngwabi; Andres Perez Lopez; Simon Dobson; Laith Jamal Abu Raddad; Patrick Tang
Journal:  Microbiol Spectr       Date:  2021-11-03

9.  SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells.

Authors:  Soeren Lukassen; Robert Lorenz Chua; Timo Trefzer; Nicolas C Kahn; Marc A Schneider; Michael Kreuter; Christian Conrad; Roland Eils; Thomas Muley; Hauke Winter; Michael Meister; Carmen Veith; Agnes W Boots; Bianca P Hennig
Journal:  EMBO J       Date:  2020-04-14       Impact factor: 11.598

10.  Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections.

Authors:  Zhen Zou; Yiwu Yan; Yuelong Shu; Rongbao Gao; Yang Sun; Xiao Li; Xiangwu Ju; Zhu Liang; Qiang Liu; Yan Zhao; Feng Guo; Tian Bai; Zongsheng Han; Jindong Zhu; Huandi Zhou; Fengming Huang; Chang Li; Huijun Lu; Ning Li; Dangsheng Li; Ningyi Jin; Josef M Penninger; Chengyu Jiang
Journal:  Nat Commun       Date:  2014-05-06       Impact factor: 14.919

View more
  3 in total

1.  Epipharyngeal Abrasive Therapy Down-regulates the Expression of Cav1.2: A Key Molecule in Influenza Virus Entry.

Authors:  Kensuke Nishi; Shohei Yoshimoto; Soichiro Nishi; Tatsuro Nishi; Ryushiro Nishi; Toshiyuki Tsunoda; Hiromitsu Morita; Hiroaki Tanaka; Osamu Hotta; Susumu Yasumasu; Kenji Hiromatsu; Senji Shirasawa; Takashi Nakagawa; Takafumi Yamano
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

2.  Epipharyngeal Abrasive Therapy (EAT) Has Potential as a Novel Method for Long COVID Treatment.

Authors:  Kazuaki Imai; Takafumi Yamano; Soichiro Nishi; Ryushiro Nishi; Tatsuro Nishi; Hiroaki Tanaka; Toshiyuki Tsunoda; Shohei Yoshimoto; Ayaki Tanaka; Kenji Hiromatsu; Senji Shirasawa; Takashi Nakagawa; Kensuke Nishi
Journal:  Viruses       Date:  2022-04-27       Impact factor: 5.818

3.  Epipharyngeal Abrasive Therapy (EAT) Reduces the mRNA Expression of Major Proinflammatory Cytokine IL-6 in Chronic Epipharyngitis.

Authors:  Kensuke Nishi; Shohei Yoshimoto; Soichiro Nishi; Tatsuro Nishi; Ryushiro Nishi; Takayuki Tanaka; Toshiyuki Tsunoda; Kazuaki Imai; Hiroaki Tanaka; Osamu Hotta; Ayaki Tanaka; Kenji Hiromatsu; Senji Shirasawa; Takashi Nakagawa; Takafumi Yamano
Journal:  Int J Mol Sci       Date:  2022-08-16       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.